Tadalafil Tablet, Film Coated
Product Images NDC 24979-729

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 24979-729). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Upsher-smith Laboratories, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Package Label (10mg 250tablets Bottle Label)

Tadalafil Tablets USP 10 mg film-coated oral tablets packaging label. The label indicates a 250-tablet quantity for prescription use only, recommended for once daily use with instructions that tablets should not be split and the entire dose taken. The labeler is Upsher-Smith Laboratories, LLC; manufactured by QILU Pharmaceutical (Hainan) Co., Ltd in China for TWi Pharmaceuticals USA, Inc.*

FDA Label Image

Package Label (10mg Bottle Label)

Label for Tadalafil Tablets USP 10 mg film-coated tablets by Upsher-Smith Laboratories, LLC. The label states a 30-tablet count, oral use, and prescription-only status. It includes dosage instructions, manufacturer and distributor details, storage conditions, and a 2D barcode placeholder area.*

FDA Label Image

Package Label (20mg 120tablets Bottle Label)

Tadalafil Tablets, USP 20 mg film-coated tablets label from Upsher-Smith Laboratories, LLC. The label states the package contains 120 tablets for once daily use, with a warning that tablets should not be split and the entire dose should be taken. It includes storage instructions and manufacturing details from QILU Pharmaceutical (Hainan) Co., Ltd., China, and TWi Pharmaceuticals USA, Inc., Paramus, NJ. The label also displays a barcode and regulatory information.*

FDA Label Image

Package Label (20mg Bottle Label)

Label for Tadalafil Tablets, USP 20 mg film-coated tablets by Upsher-Smith Laboratories, LLC. The label includes dosing instructions, storage information, and warnings. It specifies a 30-count bottle for oral use with a barcode and manufacturing details from QILU Pharmaceutical in China. The label notes prescription-only status and cautions that tablets should not be split.*

FDA Label Image

Package Label (2point5mg 500tablets Bottle Label)

Label for Tadalafil 2.5 mg film-coated tablets, USP, containing 500 tablets. The label indicates prescription use only, daily dosage instructions, and storage conditions. Manufactured by QILU Pharmaceutical (Hainan) Co., Ltd. for TWi Pharmaceuticals USA, Inc. The label includes barcode and lot/expiration placeholders.*

FDA Label Image

Package Label (2point5mg Bottle Label)

Label for Tadalafil tablets, USP 2.5 mg, film-coated oral tablets. The label indicates a 30 tablet count and states that tablets should not be split, with guidance for once daily use. Manufacturer details include QILU Pharmaceutical (Hainan) Co., Ltd. and TWi Pharmaceuticals USA, Inc. The label displays a barcode, dosage and storage instructions, and prescription-only status.*

FDA Label Image

Package Label (5mg 500tablets Bottle Label)

Label for Tadalafil 5 mg tablets, USP by Upsher-Smith Laboratories, LLC. The label shows a 500 tablet count and instructs once daily use with tablets not to be split. It includes storage and safety information, manufacturer details (QILU Pharmaceutical, China), and prescription-only status.*

FDA Label Image

Package Label (5mg Bottle Label)

Label for Tadalafil 5 mg film-coated tablets by Upsher-Smith Laboratories, LLC. The label includes dosage instructions indicating once daily use, a 30-count tablet package, and storage information. Manufacturer details list QILU Pharmaceutical (Hainan) Co., Ltd. The label features a barcode and space for lot, expiration date, serial number, and GTIN.*

FDA Label Image

Figure 5 (F005)

A line graph comparing change from baseline in IPSS total score over 12 weeks of treatment between tadalafil 5 mg tablets and placebo. The x-axis shows duration of treatment in weeks (0, 4, 8, 12), and the y-axis shows change from baseline in IPSS total score, with tadalafil showing a greater decrease over time compared to placebo. Statistically significant difference is indicated at 12 weeks.*

FDA Label Image

Figure 6 (F006)

A line graph comparing the change from baseline in IPSS total score over 12 weeks of treatment between Tadalafil 5 mg tablets and placebo. The x-axis shows treatment duration in weeks (0, 2, 4, 8, 12), and the y-axis shows change from baseline scores. The Tadalafil 5 mg group demonstrates a greater reduction in score over time compared to placebo, with a statistically significant difference at 12 weeks (p < 0.01).*

FDA Label Image

Figure 7 (F007)

A line graph showing the least squares mean change from baseline over 26 weeks of therapy comparing Tadalafil/Finasteride and Placebo/Finasteride treatments. The x-axis represents weeks of therapy (0, 4, 12, 26), and the y-axis shows the mean change from baseline. Tadalafil/Finasteride shows a greater reduction compared to Placebo/Finasteride at all measured time points, with statistical significance indicated at various weeks.*

FDA Label Image

Figure 8 (F008)

A line graph showing change from baseline in IPSS total score over 12 weeks of treatment. It compares Tadalafil 5 mg tablets and placebo, with IPSS score on the vertical axis and duration of treatment (weeks) on the horizontal axis. The graph shows greater score reduction for Tadalafil 5 mg compared to placebo, with a significant difference at 12 weeks (p < 0.01).*

FDA Label Image

Figure1 (Figure1)

A set of four line graphs showing the difference in blood pressure (BP) measurements between Tadalafil and placebo over time in hours. The graphs display changes in standing systolic BP, standing diastolic BP, supine systolic BP, and supine diastolic BP, with time on the x-axis and difference in mmHg on the y-axis, including error bars for variability.*

FDA Label Image

Figure2 (Figure2)

A two-part line graph comparing changes in systolic blood pressure over 24 hours post-dose for Tadalafil 20 mg with doxazosin 8 mg and placebo with doxazosin 8 mg. The upper graph shows standing systolic BP changes, and the lower graph shows supine systolic BP changes, both measured in mmHg over time in hours.*

FDA Label Image

Figure3 (Figure3)

A line graph showing changes in systolic blood pressure (mmHg) over 12 hours after administration of tadalafil or placebo combined with doxazosin. The graph compares blood pressure at 08:00 and 20:00 dosing times for 20 mg tadalafil plus 8 mg doxazosin and placebo plus 8 mg doxazosin, with distinct lines and markers representing each condition.*

FDA Label Image

Figure4 (Figure4)

A line graph showing plasma tadalafil concentration (µg/L) over time (hours) for three dosing regimens: single 20-mg dose, single 5-mg dose, and once-daily 5-mg dose after 5 consecutive days. Data points with error bars illustrate concentration decline and variability from 0 to 120 hours.*

FDA Label Image

Chemical Structure (Structure)

Chemical structure diagram of Tadalafil, showing its molecular framework with key bonds and atoms arranged in multiple connected rings including benzene, pyrrole, and lactam groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.